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1. Introduction 
The most recent statistics indicate that the global prevalence of diabetes mellitus, estimated 
as 366 million in 2011, will increase to 522 million by 2030 (Whiting et al., 2011). Diabetes 
mellitus is a metabolic disorder of multiple etiology characterized by chronic hyperglycemia 
with disturbances of carbohydrate, fat and protein metabolism resulting from defects in 
insulin secretion and/or insulin action (ADA, 2011). There are basically two types of 
diabetes mellitus: type 1 and type 2 diabetes mellitus. Type 1 diabetes mellitus, an 
autoimmune disease, is characterized by the loss of pancreatic ǃ-cells resulting in absolute 
insulin deficiency. It accounts for about 5-10 % of all newly diagnosed diabetes mellitus 
(ADA, 2011). On the other hand, type 2 diabetes mellitus is characterized by insulin 
resistance and ǃ cell dysfunction. It remains the most common form of diabetes mellitus and 
constitutes about 90-95 % of all diabetes cases (ADA, 2011). In spite of the availability of 
different classes of oral hypoglycemic drugs, the incidence of microvascular complications 
(nephropathy, retinopathy and neuropathy) and macrovascular complications 
atherosclerosis, coronary artery disease, peripheral arterial disease and stroke continues to 
rise unabated in diabetic patients, even with treatment (Roglic and Unwin, 2010).  
Pharmacological agents with different mechanisms of action are often combined to achieve 
optimal glycemic control (Turner et al., 1999). However, despite the use of multiple drugs, a 
lot of diabetic patients do not achieve the optimal glycemic goal (Turner et al., 1999). The 
Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective 
Diabetes Study (UKPDS) have demonstrated that intensive treatment of hyperglycemia 
reduces risk of developing microvascular and macrovascular complications (DCCT, 1993, 
UKPDS, 1998). However, recent findings indicate that intensive treatment of hyperglycemia 
is associated with higher incidence of weight gain, hypoglycemia and mortality than 
conventional therapy (Ismail-Beigi et al., 2010). These findings suggest that intensive 
therapy is not only detrimental, but limited and may not be the best. Besides, these findings 
may suggest that it is high time “hyperglycemia alone” was made the “culprit” in the 
management of diabetes mellitus. Generally, hypoglycemic drugs are incapable to prevent 
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pancreas degeneration, worsening of glycemic control and diabetic complications (DCCT, 
1993, UKPDS, 1998, Turner et al., 1999, Ball et al., 2000). All these have been linked to 
increased oxidative stress in diabetes mellitus (Figueroa-Romero et al., 2008, Giacco and 
Brownlee, 2010). The aim of this chapter is to shed more light on the prospective of 
managing diabetes mellitus more effectively by targeting both “hyperglycemia and 
oxidative stress simultaneously”. The data presented in this chapter convincingly suggest 
that the current management of diabetes mellitus may be improved upon by targeting 
hyperglycemia and oxidative stress as two potential therapeutic targets in diabetes mellitus. 
2. General overview of oxidative stress 
Considering the aim of this chapter, the general concept of oxidative stress will be discussed 
only in brief. Oxidative stress can defined as an “imbalance between oxidants and 
antioxidants in favor of the oxidants, potentially leading to damage” (Sies, 1991). According 
to Halliwell, “oxidative stress refers to a serious imbalance between reactive species 
production and antioxidant defenses” (Halliwell and Gutteridge, 2007). It occurs due to an 
increased generation and/or reduced elimination of reactive species (RS) by the antioxidant 
defense system. Oxidative stress is usually associated with oxidative damage, which is 
defined as “the biomolecular damage caused by attack of RS upon the constituents of living 
organisms” (Halliwell and Gutteridge, 2007). Most of the biologically relevant RS are either 
reactive oxygen species (ROS) or reactive nitrogen species (RNS). ROS include free radicals 
such as superoxide (O2−) and hydroxyl (OH), and non-free radicals such as hydrogen 
peroxide (H2O2). Reactive nitrogen species include free radicals such as nitric oxide (NO)  
and  nitrogen dioxide (NO2−), and non-free radicals such as peroxynitrite (OONO−) (Sies, 
1991, Halliwell and Gutteridge, 2007). The generation of RS by aerobic organisms may occur 
as by products of metabolism (e.g. during operation of  electron transfer chains), 
intentionally (e.g. during inflammation), or as a result of accidents of chemistry (such as the 
autoxidation of unstable biomolecules, e.g. dopamine) (Halliwell, 2011). Of all the RS, 
significant roles of O2−, NO, and OONO− have been implicated in diabetic cardiovascular 
complications (Johansen et al., 2005). In order to prevent oxidative damage, it is important 
that excess RS is eliminated from the cells. Oxidative damage to cellular components 
impairs cellular functions. Besides their toxicities, ROS are also required in certain 
conditions and for physiological functions. For instance, during inflammation, the 
phagocytes release ROS which kill invading bacteria. ROS generated during mild or 
moderate exercise constitute part of the mechanism of exercise- or training-induced 
adaptation (Sachdev and Davies, 2008).  
The ability of cells or tissues to withstand oxidative stress is largely dependent on the 
efficiency of the overall antioxidant defense system to scavenge excess RS,  without 
compromising the physiological roles of ROS (Halliwell, 2011). The antioxidant defense 
system consists of endogenously-synthesized antioxidants which include antioxidant 
enzymes, glutathione, vitamins, small molecules and micronutrients (Sies, 1991, Halliwell 
and Gutteridge, 2007). An antioxidant is defined as “any substance that delays, prevents or 
removes oxidative damage to a target molecule” (Halliwell and Gutteridge, 2007). 
Antioxidant enzymes are enzymes which scavenge or eliminate a variety of RS including 
those generated during biological processes (Sies, 1991, Halliwell and Gutteridge, 2007). The 
main antioxidant enzymes are superoxide dismutase (SOD),  catalase (CAT) and glutathione 
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peroxidase (GPx) (Halliwell, 2011). SOD maintains the cellular levels of O2− within the 
physiological concentrations by converting O2− to H2O2, a more stable ROS (Halliwell and 
Gutteridge, 2007, Fukai and Ushio-Fukai, 2011). CAT metabolizes H2O2 to O2 and H2O 
(Halliwell and Gutteridge, 2007). CAT exerts two enzymatic activities, depending on the 
concentrations of its substrate (H2O2) (Scibior and Czeczot, 2006). It elicits a catalytic 
function at high concentrations of H2O2, whereas it produces a peroxidatic effect at lower 
concentrations of H2O2 (Scibior and Czeczot, 2006). GPx enzymatically reduces H2O2 to O2 
and H2O using a hydrogen donor, glutathione (GSH) which is oxidized to glutathione 
disulfide (GSSG) (Lubos et al., 2011). Unlike CAT, GPx has a broader spectrum of substrates, 
detoxifying organic hydroperoxides and lipid peroxides (Lubos et al., 2011). However,  CAT 
compared to GPx has a higher KM for H2O2  and thus can protect against a higher 
concentration of H2O2  (Halliwell and Gutteridge, 2007).  
The other antioxidant enzymes include glutathione reductase (GR), glutathione S-
transferase (GST), peroxiredoxin, thioredoxin and thioredoxinreductase  (Andreyev et al., 
2005). GR scavenges O2− and OH non-enzymatically or by serving as an electron donor to 
certain enzymes involved in the metabolism of ROS (Andreyev et al., 2005, Slonchak and 
Obolens'ka, 2009). GR helps to regenerate GSH via reduction of oxidized glutathione (GSSG)  
(Slonchak and Obolens'ka, 2009). GST comprises a family of multifunctional phase II 
biotransformation enzymes with a broad spectrum for a variety of substrates including 
epoxides, carcinogens, mutagens, 4-hydroxy-2-nonenal and malondialdehyde (MDA) 
(Andreyev et al., 2005, Slonchak and Obolens'ka, 2009). It catalyzes the conjugation of many 
electrophilic compounds with GSH (Andreyev et al., 2005). These enzymes work co-
operatively together in order to scavenge RS and xenobiotics and thereby protect cells 
against oxidative damage (Halliwell, 2011). Generally, antioxidant enzymes differ from one 
another in terms of structure, tissue distribution, co-factor requirement, function, substrate 
specificity and affinity. The uniqueness of the antioxidant defense system lies in its 
capability to maintain the RS at certain steady-state levels  thereby create and maintain a 
balance between the beneficial and injurious effects of RS (Lushchak, 2010). More detailed 
information on oxidative stress including free radicals, ROS, RNS, antioxidant enzymes, 
antioxidants, antioxidant defense system, and markers of oxidative stress can be obtained 
from following references (Sies, 1991, Johansen et al., 2005, Halliwell and Gutteridge, 2007, 
Halliwell, 2011). 
3. Oxidative stress and its sources in diabetes mellitus 
Under normal conditions and in most diseases including diabetes mellitus, mitochondria are 
the main source of RS and oxidative stress. Under physiological conditions, e.g. during 
mitochondrial oxidative metabolism, the bulk of oxygen (O2) utilized is reduced to H2O, 
while less than 2% of O2 consumed is converted to O2− (Brand, 2010). O2− is an important 
ROS because it may be converted to other RS including H2O2, OH and ONOO− (Andreyev et 
al., 2005). Within physiological conditions, the body is protected from the detrimental effects 
of these free radicals by a network of antioxidant defense system. However, this defense 
system becomes impaired in diabetes mellitus and is further exacerbated by chronic 
hyperglycemia which generates ROS, resulting in oxidative stress. Some of the various 
sources of ROS and oxidative stress in diabetes mellitus include: 
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Chronic hyperglycemia is the hallmark of diabetes mellitus. Evidence implicates 
mitochondrial generation of O2− as a significant source of ROS (Andreyev et al., 2005). With 
persistent hyperglycemia, disproportionate amounts of glucose are delivered to the cells. 
This results in enhanced glucose flux through glycolysis and the tricarboxylic acid (TCA) 
cycle (Drews et al., 2010). This leads to an overdrive of the mitochondrial electron transport 
chain, which generates greater amounts of O2− more than mitochondrial SOD can 
dismutase (Wiernsperger, 2003, Brand, 2010). This tilts the normal delicate balance between 
mitochondrial ROS production and mitochondrial ROS degradation in favor of 
mitochondrial ROS generation, and oxidative stress ensues (Brand, 2010). Evidence indicates 
that hyperglycemia-induced excessive mitochondrial O2− production plays an important 
role in generating other RS in diabetes mellitus (Nishikawa et al., 2000b). Furthermore, 
glucose autooxidation produces ROS in the presence of transition metal ions (Johansen et al., 
2005). Elevated glucose in diabetes may also react with lipids, resulting in the generation of 
RS (Johansen et al., 2005). Through non-enzymatic glycation reaction, glucose can react with 
proteins to produce several intermediate products such as Amadori and Sciff base products 
before generating advanced glycosylation endproducts (AGEs) (Johansen et al., 2005). 
Evidence indicates ROS are generated at each step of these reactions. Moreover, with 
excessive glucose in diabetes, it has been shown that glucose is diverted to other pathways 
such as sorbitol and hexosamine pathways where glucose is metabolized and ROS are 
generated (Johansen et al., 2005, Figueroa-Romero et al., 2008, Giacco and Brownlee, 2010). 
3.2 Impaired antioxidant defense system 
Impaired antioxidant defense system, such as reduced levels of endogenous antioxidants, 
reduced/enhanced antioxidant enzyme activities and increased levels of oxidative stress 
markers such as MDA, is very common in diabetes mellitus (Maritim et al., 2003, Johansen 
et al., 2005, Rahimi et al., 2005, Erejuwa et al., 2010a). The insufficient scavenging of RS as a 
result of impaired antioxidant defense system in diabetes may contribute to increased 
oxidative damage. The mechanisms for the impaired antioxidant defenses in diabetes 
mellitus remain poorly understood. It may be due to non-enzymatic glycation of these 
enzymes by hyperglycemia and thereby impairs their individual functions. Furthermore, 
evidence indicates that the antioxidant enzymes produce optimal protection when they 
function together (Michiels et al., 1994). Thus, glycation of any of these antioxidant enzymes 
may impair the efficiency of the entire antioxidant defense system or network. For instance, 
if SOD activity is impaired, this may result in O2− build-up. On the other hand, if SOD 
activity is up-regulated, this may result in increased levels of H2O2. In either case, this may 
affect the activity of CAT or GPx. Similarly, if GR activity is impaired, there may be 
increased steady-state GSSG levels which will prevent regeneration of GSH, an endogenous 
antioxidant.  
3.3 Increased activity of ROS-generating enzymes 
The activities of many ROS-generating enzymes such as cyclooxygenase, xanthine oxidase, 
lipoxygenases, myeloperoxidase, NADPH oxidases and eNOS are augmented in diabetes 
(Wiernsperger, 2003). Besides, evidence implicates a role of endothelial NO synthase 
(eNOS). The eNOS produces NO which scavenges O2− in non-diabetic subjects. However, 
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the eNOS has been found to be uncoupled in diabetic blood vessels where it produces O2− 
instead of NO (Wiernsperger, 2003). Hyperglycemia might play an important role in the 
upregulation and uncoupling of ROS-generating enzymes.  
3.4 Hyperinsulinemia 
Insulin resistance characterized by hyperinsulinemia is frequent in the majority of the 
individuals with type 2 diabetic mellitus. Insulin induces the release of H2O2 when 
activating its receptors (Wiernsperger, 2003). Even though H2O2 is a non-free radical, it is 
membrane permeable and can diffuse to other sites, different from its site of production 
(Sies, 1991, Halliwell and Gutteridge, 2007). Chronic hyperinsulinemia together with the 
impaired antioxidant defenses in diabetes will lead to inefficient scavenging of H2O2. In the 
presence of transition metals such as copper and iron, H2O2 undergoes Fenton reaction to 
generate OH which is implicated in the initiation and propagation of lipid peroxidation. 
Thus, hyperinsulinemia via H2O2 formation may increase RS and contribute to oxidative 
stress and damage in diabetes mellitus. Besides, insulin stimulates the release of many 
neurotransmitters, via activation of sympathetic nervous system. Many of these 
neurotransmitters are known to generate ROS and induce oxidative stress (Wiernsperger, 
2003).  
3.5 Insulin deficiency 
Insulin deficiency is frequently observed in the diabetic patients. In some type 2 diabetic 
patients, insulin deficiency may be so severe such that the injection of exogenous insulin is 
required to control hyperglycemia (Turner et al., 1999, Cook et al., 2005). Insulin deficiency 
augments the activity of fatty acyl coenzyme A oxidase. Fatty acyl coenzyme A oxidase is an 
enzyme which is responsible for the oxidation of fatty acids, resulting in the increased 
generation of H2O2 (Schonfeld et al., 2009). H2O2 is well recognized for its role in exerting 
deleterious effects on cellular components such as proteins, nucleic acid and lipids including 
polyunsaturated fatty acids (PUFAs) (Sies, 1991, Halliwell and Gutteridge, 2007). These 
injurious effects of H2O2 can be mediated directly or indirectly through OH formation or 
reaction with transition metals (such as copper or iron) to form toxic aldehydes, which are 
highly susceptible to free radical attack (Sies, 1991, Halliwell and Gutteridge, 2007). This sets 
up a chain reaction which further propagates the formation of more free radicals or RS and 
thereby contributes to or exacerbate  oxidative stress. 
3.6 Other sources of ROS and oxidative stress in diabetes mellitus 
Diabetes mellitus is characterized by lipid abnormalities such as elevated LDL and 
cholesterol (ADA, 2011). These abnormalities are further exacerbated by the increased 
oxidizing environment which enhances the formation of oxidized LDLs (oxLDLs), glycated 
LDL and oxysterols (formed from the oxidation of cholesterol) (Johansen et al., 2005). These 
oxidized lipid products bind to specific receptor proteins or activate inflammatory proteins 
which generate ROS (Johansen et al., 2005). The import of oxLDLs in the vascular wall is the 
main mechanism by which ROS and oxidative stress induce atherosclerosis (Sies, 1991, 
Wiernsperger, 2003, Halliwell and Gutteridge, 2007). Evidence indicates that the levels of 
certain pro-oxidants such as ferritin and homocysteine are elevated in diabetes (Penckofer et 
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al., 2002). Free iron can increase ROS generation and the oxidation of LDL cholesterol. 
Similarly, homocysteine can generate ROS in the presence of transition metals which may 
enhance the oxidation of LDL cholesterol (Penckofer et al., 2002). Another source of ROS in 
diabetes mellitus is leptin. Elevated levels of leptin are associated with insulin resistance and 
diabetes mellitus. Evidence implicates a role of leptin in inducing ROS and oxidative stress 
in aortic endothelial cells in a dose-dependent manner while it produces additive effects 
with those of glucose (Wiernsperger, 2003). Other potential sources of ROS include aging, 
menopause, diet and physical activity (Penckofer et al., 2002). Increased ROS is reported in 
older people. Menopause may also enhance ROS production in older women. The levels of 
oestrogen, an antioxidant which decreases the oxidation of LDL cholesterol, usually decline 
during menopause (Penckofer et al., 2002). Aging and menopause may exacerbate oxidative 
stress since a large number of type 2 diabetics are older men and women. Consumption of 
foods rich in carbohydrates and fats, as opposed to antioxidant-enriched diets, may also 
enhance ROS formation. Sedentary lifestyle may predispose to increased ROS generation. 
This is corroborated by evidence which indicates mild or moderate, but not strenuous, 
exercise induces antioxidant defenses (Sachdev and Davies, 2008). 
4. Role of oxidative stress in the pathogenesis of diabetes mellitus  
Evidence implicates the role of oxidative stress in the different stages of the development of 
diabetes mellitus, starting from the pre-diabetes state, impaired glucose tolerance, 
postprandial hyperglycemia,  mild diabetes and finally to overt diabetes mellitus (Ceriello et 
al., 1998). Loss of ǃ-cell function, resulting from impaired secretory capacity and increased 
apoptosis, is a main occurrence in the pathogenesis of both types of diabetes (Drews et al., 
2010). Besides ǃ-cell dysfunction, insulin resistance is also a major characteristic feature of 
type 2 diabetes mellitus (Evans et al., 2003). Oxidative stress plays an important role in the 
pathogenesis of both ǃ-cell dysfunction and insulin resistance (Evans et al., 2003, Drews et 
al., 2010).  
4.1 Role of oxidative stress in β-cell dysfunction 
The ǃ-cells express low level of antioxidant enzymes such as SOD, CAT and GPx and 
thereby increase their susceptibility to oxidative stress (Tiedge et al., 1997). Increased 
mitochondrial ROS production in the ǃ-cells results from enhanced glucose or fatty acid flux  
through glycolysis and the TCA cycle (Drews et al., 2010). This generates excess O2−  which 
gives rise to other ROS and RNS. The insufficiency of antioxidant enzymes to scavenge these 
ROS leads to oxidative stress. Besides mitochondria, NADPH oxidases, nitric oxide 
synthases, and phagocytes are other key sources of ROS in the ǃ-cells (Drews et al., 2010). In 
type 1 diabetes mellitus, evidence implicates the role of ROS in impaired -cell function 
caused by autoimmune reactions, cytokines and inflammatory proteins (Drews et al., 2010). 
Similarly, in type 2 diabetes mellitus, the role of ROS is implicated in the ǃ-cell dysfunction 
as well as insulin resistance (Drews et al., 2010). The pancreas is highly susceptible to 
oxidative stress as evidenced by studies which show that H2O2 impairs insulin secretion in 
pancreatic -cells (Maechler et al., 1999) and products of oxidative stress inhibit glucose-
stimulated insulin secretion (Miwa et al., 2000). Other evidence shows that overexpression 
of antioxidant enzymes in islets or transgenic mice and antioxidants such as N-acetyl-L-
cysteine (NAC) protect against ROS-induced -cell toxicity (Tiedge et al., 1998, Drews et al., 
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2010). Research within the last decade has recognized the role of glucotoxicity as the main 
causal determinant of ǃ-cell dysfunction (Drews et al., 2010). The role of glucotoxicity in ǃ-
cell dysfunction is demonstrated by studies which indicate increased glucose concentrations 
impair insulin release in non-diabetic subjects (Marchetti et al., 2008). In contrast, improved 
glycemic control results in improved insulin secretion in patients with type 2 diabetes 
(Marchetti et al., 2008). The fact that antioxidants reduce or prevent the toxicities of elevated 
glucose on the expression of insulin mRNA, insulin content and secretion lends support to 
the role of oxidative stress in mediating the toxic effects of glucotoxicity (Tanaka et al., 1999). 
Besides glucotoxicity, lipotoxicity may also play a role in impaired ǃ-cell  function. Free fatty 
acids have been shown to uncouple mitochondrial oxidative phosphorylation and increase 
ROS formation in rat pancreatic islets (Carlsson et al., 1999), deplete pancreatic ǃ-cell insulin 
content (Bollheimer et al., 1998) and inhibit glucose-induced insulin secretion and 
biosynthesis (Zhou and Grill, 1994). Both glucotoxicity and lipotoxicity may be involved in 
ǃ-cell dysfunction in diabetes mellitus (Marchetti et al., 2008). The role of oxidative stress is 
also implicated in ǃ-cell deficit, as well as  increased apoptosis observed in humans with 
type 2 diabetes (Drews et al., 2010). 
4.2 Role of oxidative stress in insulin resistance 
Insulin resistance precedes the onset of diabetes mellitus and is influenced by factors such as 
genetic make-up and environmental factors including increased calorie intake, sedentary 
lifestyle, obesity, pregnancy and abnormally elevated levels of certain hormones (Evans et 
al., 2003). The role of oxidative stress is implicated in the pathogenesis of insulin resistance 
(Kim et al., 2006). Both pyruvate and fatty acids can serve as energy substrate in muscle and 
adipose tissue. Pyruvate is derived from glucose and other sugars, while fatty acids 
originate from fats. Once transported across the inner mitochondrial membrane, these fuel 
substrates are converted to acetyl CoA by mitochondrial enzymes. During citric acid cycle, 
oxidation of the carbon atoms of the acetyl groups in acetyl CoA generates CO2. Besides CO2 
formation, the citric acid cycle generates high-energy electrons which are carried by NADH 
and FADH2. The increased uptake of energy substrate in the muscle and adipose tissue 
enhances citric acid cycle activity. This in turn generates mitochondrial NADH more than 
required. This leads to an overdrive of the oxidative phosphorylation which increases the 
mitochondrial transmembrane proton gradient. These high-energy electrons are then 
transferred to O2  leading to production of O2− which is further converted to other ROS. 
This sets the stage for oxidative stress (Talior et al., 2003). A recent study showed that the 
skeletal muscle of  high-fat diet-induced insulin-resistant rats liberated more mitochondrial 
H2O2 and had impaired ability to maintain normal redox balance compared to the data 
obtained in the skeletal muscle of the insulin-sensitive control rats (Anderson et al., 2009). 
Similar findings were observed in insulin-resistant, morbidly obese human subjects 
(Anderson et al., 2009). This study provides strong evidence in support of a role of 
mitochondrial ROS production and oxidative stress in the pathogenesis of insulin resistance.  
Various mechanisms by which oxidative stress contributes to insulin resistance have been 
identified. These include oxidative stress-impaired insulin-induced GLUT4 translocation in 
adipocytes (Rudich et al., 1998), oxidative stress-induced impairment in insulin stimulation 
of protein kinase B and glucose transport in adipocytes (Rudich et al., 1999), oxidative 
stress-induced interactions between the PI3-kinase-dependent signaling pathway and 
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activation of p38 MAPK  (Kim et al., 2006), and interruption of insulin-induced cellular 
redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 
adipocytes (Tirosh et al., 1999). Other studies indicate that oxidative stress can directly 
induce considerable insulin resistance in skeletal muscle by interfering with insulin 
signaling, glucose uptake and glycogen synthesis (Dokken et al., 2008). This oxidative stress-
induced insulin resistance is mediated in part through reduced insulin-modulated 
suppression of glycogen synthase kinase-3 (GSK-3beta) (Dokken et al., 2008; Henriksen, 
2010). Evidence has also implicated a role of inducible nitric oxide synthase and NO donor 
in the degradation of insulin receptor substrate-1. Increased S-nitrosylation of certain 
molecules or pathways involved in insulin signaling such as insulin receptor, insulin 
receptor substrate-1, and protein kinase B/Akt in skeletal muscle have also been reported to 
play an important role in insulin resistance (Carvalho-Filho et al., 2009). 
In order to protect against increased glucose-induced oxidative stress (Talior et al., 2003), 
cells tend to respond by limiting more energy fuel or substrates from gaining access into the 
cells. Cells may utilize various mechanisms, including inhibition of ǂ-ketoglutarate 
dehydrogenase, to limit the amount of NADH available for the oxidative phosphorylation. 
Therefore, to limit insulin-dependent nutrient uptake into the cells, the insulin receptors 
become less sensitive to the action of insulin. This marks the onset of insulin resistance - a 
phenomenon whereby normal amounts of insulin can no longer activate the glucose 
transport system in insulin-sensitive tissues such as skeletal muscle and adipose tissue. This 
results in enhanced steady-state glucose levels in the blood. It is suggested that, in this 
setting, insulin resistance may be a compensatory mechanism employed by the cells to 
prevent further uptake of insulin-stimulated glucose and fatty acids (Hoehn et al., 2009). 
This compensatory mechanism may result in reduced formation and accumulation of RS 
leading to reduced oxidative stress and damage. With persistently increased blood glucose 
levels, hyperglycemia ensues leading to overt type 2 diabetes mellitus.  
4.3 Could antioxidants play a role in preventing diabetes mellitus and/or its 
progression? 
In view of evidence which implicates a role of oxidative stress in ǃ-cell dysfunction and 
insulin resistance, the question that arises is: could antioxidants play a role in preventing 
diabetes mellitus and/or its progression? As discussed earlier, there is a possibility for such 
a role of antioxidants. Antioxidants such as vitamin C, vitamin E, ǃ-carotene, ǂ-lipoic acids 
and honey have been shown to ameliorate hyperglycemia through increased ǃ-cell mass and 
insulin secretion. However, at the moment, the evidence to recommend or prescribe 
antioxidants for the prevention of diabetes mellitus is very weak. Instead,  efforts should be 
made to create and increase the awareness on (1) the role of ROS and oxidative stress in the 
pathogenesis and/or progression of diabetes mellitus and (2) the importance of increased 
consumption of antioxidant-enriched diets including fruits and vegetables, as opposed to 
increased calorie intake. The recommendation for increased consumption of fruits and 
vegetables is very important because even in the developed countries, majority of the 
population do not meet these requirements. The importance of exercise should also not be 
left out. These could be achieved by incorporating into educational curricula - at all levels of 
education. In addition, those who are already diabetic should be enlightened on the 
importance of maintaining good glycemic control in order to prevent or delay the 
progression or complications of diabetes mellitus. Diabetic patients also need to be informed 
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on the need for adherence to dietary regimens and compliance to prescribed medications. 
These recommendations could also be an important component of training received by 
healthcare providers.  
5. Role of oxidative stress in the complications of diabetes mellitus 
There is strong evidence implicating a role of oxidative stress in diabetic nephropathy, 
retinopathy and neuropathy which constitute the microvascular complications (Figueroa-
Romero et al., 2008, Giacco and Brownlee, 2010, Brownlee, 2005). Similarly, a role of 
oxidative stress is implicated in the macrovascular complications (coronary artery disease, 
peripheral arterial disease and cerebrovascular disease) (Giacco and Brownlee, 2010, 
Brownlee, 2005). This section highlights the different mechanisms by which hyperglycemia 
causes diabetic complications.  
5.1 Hyperglycemia-enhanced polyol pathway  
The polyol pathway comprises two enzymes: aldose reductase (AR) and sorbitol 
dehydrogenase (SDH) (Brownlee, 2005). AR reduces a broad spectrum of substrates such as 
glucose, galactose, methylglyoxal, glucosone, deoxyglucosone and lipid-derived aldehydes 
(Petrash, 2004). Under euglycemic conditions, glucose is not reduced by AR. The bulk of 
glucose is normally phosphorylated by hexokinase to produce glucose-6-phosphate, a 
substrate for glycolysis and pentose phosphate pathway. However, under hyperglycemic 
conditions, AR reduces glucose to sorbitol (Brownlee, 2005). Sorbitol is oxidized to fructose by 
SDH (Giacco and Brownlee, 2010). With chronic hyperglycemia, the AR pathway becomes 
enhanced leading to increased formation of sorbitol. As a result of activated AR pathway, 
there is increased consumption of NADPH (as an obligate co-factor) by AR (Figueroa-Romero 
et al., 2008). The GR also requires NADPH, as co-factor, for the regeneration of GSH, an 
endogenous scavenger of ROS. Therefore, increased utilization of NADPH caused by 
enhanced activity of AR reduces intracellular concentration of GSH. Reduced levels of GSH 
will impair the activity of GPx which utilizes GSH as a hydrogen donor (Halliwell and 
Gutteridge, 2007). Taken together, decreased NADPH impairs GR activity, reduces GSH level 
and impairs GPx activity. This impairs the antioxidant defense network and increases cellular 
susceptibility to oxidative stress. NO has been shown to inhibit AR activity in diabetes 
(Chandra et al., 2002). In view of evidence which indicates ROS can decrease NO 
bioavailability, therefore, increased oxidative stress in diabetes will further augment AR 
activity. Thus, hyperglycemia-enhanced polyol pathway will exacerbate oxidative stress in 
diabetes mellitus.  
Besides, the increased levels of sorbitol caused by enhanced AR activity increase the 
osmolality of intracellular milieu. Sorbitol, myoinositol, glycerophosphorylcholine, betaine 
and taurine are physiological osmolytes which help to maintain homeostasis in cells such as 
renal medullary cells (Yancey and Burg, 1989). Thus, as a compensatory mechanism, this 
leads to efflux of intracellular osmolytes (Figueroa-Romero et al., 2008). Some of these 
osmolytes e.g. myoinositol play a vital role in signaling transduction, while others such as 
taurine are endogenous antioxidants (Figueroa-Romero et al., 2008). Hence, increased 
sorbitol formation reduces endogenous antioxidants and other important osmolytes. This 
further impairs cellular function and increases intracellular susceptibility to oxidative stress. 
In contrast, the SDH pathway generates fructose from sorbitol. Similar to AR pathway, 
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chronic hyperglycemia increases the activity of SDH which results in the formation of high 
amounts of fructose (Figueroa-Romero et al., 2008). Increased SDH activity result in an 
increased NADH:NAD+ ratio, which may inhibit oxidation of triose phosphates (Nishikawa 
et al., 2000a). Accumulation of triose phosphates increases de novo synthesis of 
diacylglycerols (DAG) which activate protein kinase C. Increased levels of triose phosphate 
may also increase generation of methylglyoxal, a potent AGE-precursor. Besides, increased 
fructose levels may enhance glycation and further contribute to reduced levels of NADPH, 
impaired antioxidant defenses and formation of AGEs.  
5.2 Hyperglycemia-enhanced formation of advanced glycation end products  
Advanced glycation end products (AGEs)  are adducts formed non-enzymatically by the 
reaction between reducing carbohydrates and proteins, DNA, or lipids  (Ahmed, 2005). 
AGEs also include products that are formed non-enzymatically from the reaction between 
AGE precursors, glycated sugars or oxidized products of fatty acid (in arterial endothelial 
cells) and protein (Giacco and Brownlee, 2010). They are produced through three major 
pathways: (1) convertion of glucose to glyoxal; (2) degradation of Amadori products to 3-
deoxyglucosone; and (3) conversion of glyceraldehyde-3-phosphate to methylglyoxal 
(Nishikawa et al., 2000a, Ahmed, 2005, Figueroa-Romero et al., 2008). In diabetes mellitus, 
the levels of AGEs become elevated as a result of chronic hyperglycemia (Duran-Jimenez et 
al., 2009). The formation of AGEs occurs in different stages. During these stages of AGE 
formation, a number of highly reactive intermediates and cross-linkers, which enhance the 
binding affinity of AGEs to proteins, are also formed (Ahmed, 2005). AGEs can inhibit the 
antiproliferative effects of nitric oxide (Maritim et al., 2003). AGEs bind to and modify 
intracellular proteins thereby altering their functions (Giacco and Brownlee, 2010). In the 
vasculature, AGEs interact with cell surface protein or extracellular matrix components 
resulting in the formation of cross-linked proteins which enhance stiffening within the 
arterial vessel (Ahmed, 2005). AGEs can also modify plasma proteins which in turn activate 
receptor for advanced glycation end products (RAGE) on cells such as macrophages, 
vascular endothelial and smooth muscle cells (Giacco and Brownlee, 2010). AGEs can bind 
directly to and activate the receptors for AGEs.(Griesmacher et al., 1995, Ahmed, 2005).  
The binding of AGEs or AGE-modified plasma proteins to RAGE induces the release of ROS 
(Nishikawa et al., 2000a; Ahmed, 2005; Giacco and Brownlee, 2010). The ROS activate the 
expression of several genes and proteins that are involved in inflammatory cascade and 
implicated in the pathogenesis of diabetic cardiovascular disease. These genes and proteins 
include nuclear factor kappa , tumor necrosis factor ǂ, interleukin-1 and granulocyte-
macrophage colony-stimulating factor (Nishikawa et al., 2000a, Ahmed, 2005, Giacco and 
Brownlee, 2010).  
5.3 Hyperglycemia-activated protein kinase C pathway  
Protein kinase C (PKC) is an enzyme that modulates the functions of other proteins through 
their phosphorylation. PKC is activated by the elevated level of DAG, derived from  
enhanced formation of triose phosphate via hyperglycemia (Giacco and Brownlee, 2010). 
Hyperglycemia may also increase DAG content through phosphatidylcholine hydrolysis 
(Nishikawa et al., 2000a). In diabetes, elevated levels of triose phosphate occur through 
increased de novo synthesis due to inhibition of glycolytic enzyme glyceraldehyde phosphate 
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dehydrogenase (GAPDH) by increased ROS (Giacco and Brownlee, 2010). Besides DAG, 
evidence indicates that AGEs can also activate PKC pathway to increase the expression of 
vascular endothelial growth factor (VEGF) (Ahmed, 2005). Similarly, increased ROS levels in 
vascular endothelial cells may also enhance PKC pathway (Nishikawa et al., 2000a). 
Enhanced PKC activity induces several cytokines and protein signals including 
plasminogen activator inhibitor (PAI-1), NF-κB, NAD(P)H oxidases, endothelin-1, 
transforming growth factor ǃ (TGF-ǃ) and extracellular matrix (ECM) (Nishikawa et al., 
2000a). These pathological alterations have been implicated in basement membrane 
thickening, vasoconstriction, altered capillary permeability, hypoxia and activation of 
angiogenesis (Nishikawa et al., 2000a, Figueroa-Romero et al., 2008).  
5.4 Hyperglycemia-enhanced hexosamine pathway  
Evidence has implicated the role of hexosamine pathway in the toxic or adverse effects of 
hyperglycemia in diabetes mellitus (Schleicher and Weigert, 2000). Under physiological 
conditions, a small quantity of fructose-6 phosphate derived from glycolysis is diverted to 
the hexosamine pathway. Glutamine: fructose-6 phosphate amidotransferase (GFAT) then 
converts fructose-6 phosphate to glucosamine-6 phosphate, which is converted to uridine 
diphosphate-N-acetylglucosamine (UDP-GlcNAc) (Schleicher and Weigert, 2000). The 
enzyme O-GlcNAc transferase then utilizes UDP-GlcNAc as a substrate, fixing O-GlcNAC 
to protein residues of transcription factors such as Sp1 and thus modify their expression 
(Figueroa-Romero et al., 2008). Similar to the other pathways, with chronic hyperglycemia, 
the hexosamine pathway becomes enhanced (Figueroa-Romero et al., 2008, Schleicher and 
Weigert, 2000). This leads to increased formation of UDP-GlcNAc and increased activity of 
O-GlcNAc transferase, with consequent alterations in gene expression (Figueroa-Romero et 
al., 2008). This pathway is implicated in the hyperglycemia-mediated increases in the 
transcription of TGF-ǂ and TGF-ǃ1. Over-expression of these transcription factors such as 
TGF-ǃ1 is known to activate the proliferation of collagen matrix, basement membrane 
thickening and inhibition of  mesangial cell  mitogenesis, thus contributing to microvascular 
complications such as nephropathy (Schleicher and Weigert, 2000).  
5.5 Hyperglycemia-activated Poly-ADP Ribose Polymerase (PARP) pathway 
Poly(ADP-ribose) polymerase (PARP) is a family of enzymes that detect single- and double-
stranded DNA and repair damaged DNA (Virag and Szabo, 2002). Activation of PARP is a 
direct cellular response to metabolic- or chemical-induced DNA damage. Once PARP senses 
and identifies a damaged DNA, it binds to the DNA and forms homodimers and catalyzes 
the cleavage of nicotinamide adenine dinucleotide (NAD+) into nicotinamide and ADP-
ribose (Virag and Szabo, 2002). It then uses ADP-ribose to synthesize a poly(ADP-ribose) 
chain (PAR) which serves as a signal for several DNA repairing enzymes such as DNA 
ligase III and DNA polymerase beta (polǃ). In hyperglycemic environment, there is 
increased ROS formation leading to oxidative damage which activates PARP. As a result of 
NAD+ utilization, this depletes cellular NAD+ stores and induces a progressive ATP 
depletion. This further increases the vulnerability of cells to oxidative stress and damage as 
well as cell death (Figueroa-Romero et al., 2008). Available evidence suggests that PARP’s 
catalytic activity may cause altered gene expression, increased oxidative stress and 
diversion of glycolytic intermediates to other pathogenic pathways (Figueroa-Romero et al., 
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2008). A recent study demonstrated the beneficial effects of PARP inhibition in diabetic 
complications (Lupachyk et al., 2011).  
5.6 Hyperglycemia-induced mitochondrial O2
−
overproduction  
Recent data indicates that hyperglycemia-induced mitochondrial O2− overproduction is the 
sole underlying mechanism (directly or indirectly) by which hyperglycemia induces cellular 
damage (Giacco and Brownlee, 2010). During mitochondrial oxidative phosphorylation, 
O2− is generated due to leakage of electrons from electron transport chain (ETC) on 
molecular oxygen. In euglycemic environment, about 0.2–2% of O2 utilized by the 
mitochondria is reduced to O2− (Bashan et al., 2009, Brand, 2010). The antioxidant defense 
network maintains the mitochondrial level of ROS within physiological concentrations 
(Andreyev et al., 2005, Brand, 2010). However, in hyperglycemic environment, enhanced 
glucose flux through glycolysis and TCA causes an overdrive of the mitochondrial ETC 
resulting in mitochondrial dysfunction and increased ROS formation (Bashan et al., 2009; 
Brand, 2010). Elevated levels of ROS lead to oxidative stress and damage. Oxidative damage 
to DNA can activate Poly(ADP-ribose) polymerase (PARP) pathway (Wei, 1998). 
Besides this pathway, evidence suggests that hyperglycemia, via O2− overproduction , 
inhibits G6PDH. G6PDH is the rate-limiting enzyme of the pentose phosphate pathway 
necessary for generating reducing equivalents to the antioxidant defense system (Brand, 
2010). Inhibition of G6PDH leads to increased levels of glycolytic intermediates resulting in 
increased flux into these pathways. For instance, glyceraldehyde 3-phosphate can non-
enzymatically be converted to methylglyoxal which activates AGEs pathway (Giacco and 
Brownlee, 2010). Similarly, glyceraldehyde 3-phosphate is a precursor of DAG which can 
activate PKC pathway. Increased levels of fructose 6-phosphate will increase flux through 
the hexosamine pathway (Giacco and Brownlee, 2010). Furthermore, reduced levels of 
G6PDH result in increased glucose concentrations which further enhances flux through the 
polyol pathway. The aldose reductase pathway becomes intensified leading to increased 
formation of sorbitol. This sets up a chain reaction that continuously activates one pathway 
or the other generating ROS which may cause DNA damage. This causes activation of PARP 
pathway. Thus, virtually all these pathways, namely polyol pathway, formation of AGEs 
pathway, PKC pathway, hexosamine pathway, and poly-ADP ribose polymerase (PARP) 
pathway, can be activated by hyperglycemia-induced mitochondrial O2− overproduction. 
6. Interrelation among glycemic control, oxidative stress and diabetic 
complications  
So far, this chapter has identified the various sources of oxidative stress in diabetes mellitus. 
It has also presented evidence that indicates hyperglycemia enhances formation of ROS in 
diabetes mellitus. It has also shown that hyperglycemia-induced oxidative stress plays an 
important role in the activation of several pathogenic pathways implicated in the 
pathogenesis of diabetic complications. Generally, the mechanisms by which hyperglycemia 
causes cellular damage can be classified into two groups (Nishikawa et al., 2000a). The first 
group of mechanisms entails constant acute fluctuations in cellular metabolism which are 
reversible following restoration of euglycemia. The second group of mechanisms involves 
cumulative changes in long-lived macromolecules which are irreversible even after 
euglycemia is restored (Nishikawa et al., 2000a). Studies have demonstrated the beneficial 
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effects of reduced hyperglycemia or glycemic control on the risk of developing diabetic 
complications (DCCT, 1993, UKPDS, 1998). Nevertheless, recent findings suggest that 
treatment of chronic hyperglycemia to achieve optimal glycemic goal in diabetic patients is 
limited and detrimental (Ismail-Beigi et al., 2010). It is recommended that the consequences 
(higher mortality rate, hypoglycemia and weight gain) should be weighed against the 
benefits of intensive therapy (Ismail-Beigi et al., 2010). Besides, available evidence indicates 
that achieving and/or maintaining optimal glycemic control in diabetic patients is difficult 
(Turner et al., 1999, Cook et al., 2005). The difficulty in maintaining optimal glycemic control 
is attributed to deterioration of pancreatic ǃ-cell function, which is linked to hyperglycemia-
induced oxidative stress (Drews et al., 2010). Interestingly, even in diabetic patients given 
pancreatic transplants, diabetic complications such as nephropathy continued to deteriorate 
at least five years after their diabetes had been cured (Fioretto et al., 1998). This contradicts 
evidence that links hyperglycemia to diabetic complications. Therefore, this section attempts 
to explain the interrelation among glycemic control, oxidative stress and diabetic 
complications and possible role of hypoglycemic drugs (and/or insulin) and antioxidants in 
the management of diabetic complications by answering the following questions: 
1. Does reduced or intensive therapy of hyperglycemia prevent induction or development 
of oxidative stress? 
2. Does reduced or intensive therapy of hyperglycemia prevent diabetic complications?  
3. Why does reduced or intensive therapy of hyperglycemia not prevent diabetic 
complications? 
4. Could there be a role of antioxidants in the management of diabetic complications? 
5. Could there be a role of hypoglycemic drugs (and/or insulin) and antioxidants in the 
management of diabetic complications? 
6.1 Does reduced or intensive therapy of hyperglycemia completely restore or 
ameliorate oxidative stress? 
Hyperglycemia induces oxidative stress in diabetes mellitus. However, does evidence indicate 
that reduced or intensive treatment of hyperglycemia completely prevent development of 
oxidative stress? This section aims to answer this important question by presenting both 
experimental and clinical data. In diabetic rats, after two months of poor glycemic control, re-
institution of good glycemic control for seven additional months partially reduced the elevated 
caspase-3 activity, levels of NF-k, lipid peroxides and nitric oxides with no beneficial effect on 
nitrotyrosine formation. In contrast, after six months of poor glycemic control, re-institution of 
good glycemic control for seven additional months demonstrated no significant effects on the 
elevated caspase-3 activity, NF-k, and oxidative stress parameters (Kowluru, 2003, Kowluru 
et al., 2004). In another follow up study, after six months of poor glycemic control, 
normalization of hyperglycemia for another 6 months also had no significant effect on retinal 
nitrotyrosine levels, neither did oxidative stress parameters improve (Kowluru et al., 2007). 
Other studies have also shown that reduced hyperglycemia does not completely restore redox 
status (Rahimi et al., 2005, Erejuwa et al., 2010a, Erejuwa et al., 2011b).  
Evidence suggests that proteins (collagen) are likely to be glycated irrespective of blood 
glucose levels (Monnier et al., 1999). In patients with type 2 diabetes mellitus, insulin 
treatment only partially improved oxidative stress parameters (Seghrouchni et al., 2002). 
This is evidenced by the elevated levels of thiobarbituric acid reactive substances and 
reduced erythrocyte GSH (Seghrouchni et al., 2002). In type 2 diabetic patients, treatment 
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with gliclazide for 12 weeks ameliorated oxidative stress better than did glibenclamide 
(Fava et al., 2002). Available data from DCCT and Epidemiology of Diabetic Complications 
and Interventions (EDIC) Trial indicated that type 1 diabetic patients in the intensive 
therapy group still had increased levels of protein glycation products and AGEs despite 
intensive treatment (Genuth et al., 2005). However, protein glycation and AGE formation 
were less compared with those in the conventional treatment group (Genuth et al., 2005).  
The data highlighted in this section reveal that reduced or intensive therapy of 
hyperglycemia does not completely prevent induction of oxidative stress. In other words, 
once hyperglycemia (either via mitochondrial O2− overproduction or other mechanisms) 
activates any of these mechanistic pathways (especially the polyol pathway), intensive 
therapy or even normalization of hyperglycemia (which is even difficult with the current 
hypoglycemic drugs) would have limited effects on oxidative stress. Once oxidative stress is 
induced in diabetes mellitus, it can enhance the generation of ROS and initiate redox-chain 
reactions which may activate various inflammatory proteins and signaling pathways 
including all the abovementioned mechanistic pathways. Even if normal glucose level is 
restored, these inflammatory proteins and signaling pathways on their own could cause 
oxidative stress and/or sustain the oxidative stress originally or previously induced by 
hyperglycemia. Thus, with or without hyperglycemia, the resulting ROS and oxidative 
stress secondary to hyperglycemia would suffice to activate some of these pathways and set 
the stage for oxidative stress or exacerbate the already developed or existing oxidative 
stress. Besides, evidence implicates a role of oxidative stress in many neurodegenerative 
disorders such as hypertension, cancer and Alzheimer’s disease. All of these disorders are 
characterized by euglycemia. Therefore, it means or suggests that oxidative stress can be an 
entirely independent phenomenon which can exist even with normalization of 
hyperglycemia. 
6.2 Does reduced or intensive therapy of hyperglycemia prevent diabetic 
complications? 
Data from animal and human studies indicate that intensive therapy may delay the 
progression of diabetic complications, but does not prevent diabetic complications. A study 
that investigated the effect of improved glycemic control on the progression of retinopathy 
in diabetic dogs found that diabetic dogs with 5-year poor glycemic control developed 
diabetic retinopathy while those with 5-year good glycemic control had no diabetic 
retinopathy (Engerman and Kern, 1987). The third group comprised diabetic dogs with 2.5-
year poor glycemic control. It was observed that these diabetic dogs did not develop 
diabetic retinopathy. However, the dogs later developed diabetic retinopathy despite 2.5-
year good glycemic control (Engerman and Kern, 1987). The study further revealed that the 
extent of pathology of diabetic retinopathy in the third group (with 2.5-year poor glycemic 
control + 2.5-year good glycemic control) was similar to that of the dogs with 5-year poor 
glycemic control  (Engerman and Kern, 1987). Similarly, in sucrose-fed diabetic rats, cure of 
diabetes via islet transplantation at 12 weeks (but only at 6 weeks after the confirmation of 
diabetes) did not prevent lesions or progression of diabetic retinopathy (Hammes et al., 
1993). Kowluru and colleagues (2007) also reported that after 6 months of poor glycemic 
control in rats, normalization of hyperglycemia for 6 months had no effect on the lesions or 
pathology of diabetic retinopathy.  
www.intechopen.com
Oxidative Stress in Diabetes Mellitus: 
Is There a Role for Hypoglycemic Drugs and/or Antioxidants? 
 
231 
In type I diabetic patients whose diabetes had been cured (through pancreas transplantation) 
but still had diabetic nephropathy, the thickness of glomerular and tubular basement 
membranes was still similar at 5 years versus baseline values. In contrast, it was significantly 
reduced only by the 10th year versus baseline values. The study further showed that while 
mesangial fractional volume had increased by the 5th year, it significantly decreased by the 
10th year (Fioretto et al., 1998). In the DCCT, due to the considerable benefits of intensive 
therapy, patients in the conventional therapy group were transitioned to intensive therapy 
group (DCCT, 1993). A long-term follow-up study under the EDIC Trial (DCCT/EDIC, 2002, 
DCCT/EDIC, 2003, Pop-Busui et al., 2009) showed that patients who were formerly in the 
intensive therapy group had lower incidence of diabetic microvascular complications than the 
patients who were originally in the conventional treatment group, despite 8 years of similar 
and normalized glycemic control in the EDIC trial (DCCT/EDIC, 2002). It was further reported 
that the conventionally treated-DCCT patients who were transitioned to intensive therapy 
group in the EDIC trial still had greater incidence of macrovascular pathology or 
complications (Nathan et al., 2003, Nathan et al., 2005, Cleary et al., 2006, Patel et al., 2008). 
Evidence from clinical trials also suggests that the incidence or development of diabetic 
complications is more likely to depend on the intensity of oxidative stress than on the level of 
glycemic control (Monnier et al., 1999, Genuth et al., 2005). Besides, evidence indicates that the 
degree of insulin resistance correlates with the onset of diabetic complications, independently 
of glycemic levels (Chillaron et al., 2009). In type 2 diabetic patients, it was reported that 
gliclazide treatment delayed the progression of diabetic nephropathy only, whereas it 
produced no significant effect on the development or progression of retinopathy or 
macrovascular complications (Patel et al., 2008). These findings are very important because 
gliclazide is one of the few hypoglycemic agents with an antioxidant effect (Fava et al., 2002).  
It is evident from the different aforementioned hyperglycemia-induced mechanistic pathways 
and the data (both experimental and clinical) presented in this section that the pathogenesis of 
diabetic complications is a complex process. It involves oxidative stress and ROS-activated 
pathways including several inflammatory proteins, cytokines and growth factors. It is clear 
that hyperglycemia exerts long-term injurious effects in patients with type 1 and type 2 
diabetes mellitus. Similar long-lasting detrimental effects of hyperglycemia also occur in 
animals (dogs). In both animals and humans with diabetes, glycemic control only delays the 
development or progression of diabetic complications. It does not prevent or completely 
restore diabetic complications. This is understandable in view of the fact that these diabetic 
complications are not primary effects of hyperglycemia but are its sequelae (secondary effects). 
In fact, in few cases in which normalization of hyperglycemia or cure of diabetes mellitus do 
prevent diabetic complications, it has to be initiated at a very early stage of the disease and 
maintained for several years. Overall, these findings clearly show that intensive therapy or 
normalization of hyperglycemia does not prevent diabetic complications. 
6.3 Why does reduced or intensive therapy of hyperglycemia not prevent diabetic 
complications? 
Investigators have introduced different phrases to describe this concept or observation in 
which reduced or intensive therapy of hyperglycemia does not prevent diabetic 
complications. Some of these phrases include ‘‘glycemic memory”, “hyperglycemic 
memory”, “metabolic memory’’ or “lasting memory”. Glycemic memory is a term that refers 
to the development of diabetic complications during post-hyperglycemic normoglycemia 
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(Nishikawa et al., 2000a). It is a phenomenon whereby early glycemic milieu or environment 
is remembered in many target organs such as heart, eye, nerve and kidney. Evidence 
suggests that oxidative stress may contribute to the inability of reduced or intensive 
treatment of hyperglycemia to prevent diabetic complications (Ceriello et al., 2009). It is 
proposed that glycemic memory could involve two stages: induction and perpetuation 
(Nishikawa et al., 2000a). During induction, hyperglycemia generates increased ROS levels. 
This may result from increased production of reducing equivalents formed from overdrive 
of the mitochondrial ETC. As a result of increased ROS, cellular dysfunction and mutations 
in mitochondrial DNA may occur (Wei, 1998). On the other hand, perpetuation, which is 
glycemic memory itself, could occur because ROS-induced mutated mitochondrial DNA 
would encode defective ETC subunits (Nishikawa et al., 2000a). This hypothesis of defective 
mitochondrial DNA subunits seems valid. Two years after this hypothesis, a study 
demonstrated that methylglyoxal modified mitochondrial proteins causing disturbances in 
mitochondria in kidney of rats (Rosca et al., 2002). The study further showed that 
methylglyoxal produced an inhibitory effect on the tricarboxylic acid (TCA) cycle and the 
electron respiratory chain in kidney of rats. In another related study, it was shown that 
methylglyoxal-modified mitochondria considerably augmented O2− production,, 
independently of the level of hyperglycemia, and were characterized by oxidative damage 
(Rosca et al., 2005). 
Furthermore, Ihnat and colleagues (2007) also provided evidence in support of the role of 
oxidative stress in mediating the hyperglycemic memory (Ihnat et al., 2007). The authors 
showed that in human endothelial and ARPE-19 retinal cells, the levels of protein kinase C-
beta, NAD(P)H oxidase subunit p47phox, BCL-2-associated X protein, 3-nitrotyrosine, 
ffibronectin and poly (ADP-ribose) remained elevated for 1 week after the levels of glucose 
had normalized. The study showed that inhibition of ROS production using antioxidant 
alpha-lipoic acid prevented the induction of these glucose-induced oxidative stress markers 
(Ihnat et al., 2007). Similar findings were also reported in aortic endothelial cells both in 
vitro and in non-diabetic mice (El-Osta et al., 2008). The study showed that short-term 
hyperglycemic spikes produced long-lasting effects on vascular cells (El-Osta et al., 2008). 
This suggests that transient spikes of hyperglycemia may be an HbA1c-independent risk 
factor for diabetic complications (El-Osta et al., 2008). A recent study also indicated that 
elevated glucose levels caused continual changes in cell viability and apoptosis-related gene 
expressions even after recovery of normoglycemia (Wei et al., 2011). The changes were 
associated with increased ROS production (Wei et al., 2011). Besides, evidence implicates the 
role of protein glycation and formation of AGEs in metabolic memory (Genuth et al., 2005, 
Ceriello et al., 2009). AGEs may reduce NADPH and impair antioxidant system which in 
turn can generate more ROS (Ahmed, 2005). Data from the DCCT suggest that the tendency 
of collagen to be glycated is less dependent on the level of blood glucose (Monnier et al., 
1999). It was also demonstrated that both conventional and intensive therapies did not 
prevent protein glycation and formation of AGEs (Genuth et al., 2005). The data further 
revealed that the incidences of retinopathy and nephropathy were significantly associated 
with the levels of protein glycation and AGEs (Genuth et al., 2005). This phenomenon 
termed “glycemic memory” has also been corroborated in several other studies (Nathan et 
al., 2005, Holman et al., 2008).  
Recent findings indicate that elevated oscillating glucose concentrations may contribute to 
increased risk for cardiovascular diabetic complications (Ceriello et al., 2008). As 
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demonstrated by Ceriello and colleagues (2008), using a euinsulinemic hyperglycemic 
clamp, glucose at 5, 10, and 15 mmol/l was given in rising steps as a single "spike", and 
oscillating between basal and high levels over 24-hour in non-diabetic subjects and type 2 
diabetic patients. The authors reported that glucose at 10 and 15 mmol/l led to a 
concentration-dependent fasting blood glucose-independent impaired endothelial function 
and increased intensity of oxidative stress in both non-diabetic subjects and type 2 diabetic 
patients (Ceriello et al., 2008). The study also revealed that oscillating glucose concentrations 
between 5 and 15 mmol/l every 6 hour for 24 hours caused further significant impairments 
in endothelial function and induced oxidative stress compared with continuous 10 or 15 
mmol/l glucose (Ceriello et al., 2008). These findings are very relevant because the current 
management of diabetes mellitus (including intensive therapy) does not control 
postprandial hyperglycemia. Besides, both endothelial function and oxidative stress are 
implicated in the pathogenesis of diabetic micro- and macrovascular complications. 
Oxidative stress also plays an important role in endothelial dysfunction (Sies, 1991, 
Halliwell and Gutteridge, 2007). This study is also remarkable because it shows that 
oscillating levels of glucose result in endothelial dysfunction and induced oxidative stress 
even in non-diabetic subjects (euglycemia). These postprandial hyperglycemia fluctuations 
may contribute to the continuous deterioration of diabetic complications, despite restoration 
of euglycemia. Therefore, postprandial hyperglycemia-induced endothelial dysfunction and 
oxidative stress may explain the mechanism of glycemic or hyperglycemic memory.  
The findings indicate that ROS-induced mutated DNA mitochondria may continuously 
generate RS (Nishikawa et al., 2000a). The data also reveal that AGEs can modify or glycate 
protein content of mitochondrial TCA cycle and the electron respiratory chain (Ceriello, 
2009, Ceriello et al., 2009). Irrespective of the level of glycemic control, all these will generate 
RS and trigger cellular injury. Hence, it does suggest that oxidative stress in diabetes 
mellitus can exist as an independent entity. As explained previously, oxidative stress is also 
implicated in other disorders characterized by euglycemia. Since hyperglycemia enhances 
the pathogenic pathways of diabetic complications via oxidative stress, therefore, whether 
hyperglycemia is normalized or the recommended optimal glycemic goal ≤ 6.5% HbA1c is 
achieved and/or maintained, the already existing oxidative stress can activate these same 
mechanistic pathways and thus propagate glycemic memory (induce diabetic 
complications). 
6.4 Could there be a role of antioxidants in the management of diabetic 
complications? 
Since oxidative stress is implicated in the pathogenesis of diabetes and its complications, 
there ought to be a place for antioxidants in the treatment of diabetes mellitus. However, 
previous clinical trials using antioxidants have yielded both promise and inconsistent 
results. Even though the data from the large scale clinical trials are inconclusive, it is 
noteworthy that many of those clinical trials were characterized by inappropriate study 
designs or several limitations (Johansen et al., 2005, Penckofer et al., 2002, Wierzba, 2005, 
Robinson et al., 2006, Willcox et al., 2008). These include: trials did not address specific 
diabetic populations; some studies included both healthy and unhealthy subjects; no data 
establishing the occurrence of oxidative stress in the patients before treatment and 
comparing such data with those obtained after treatment; the short duration of treatment; 
most of the trials were performed with vitamins A, C and E without consideration for other 
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antioxidants; the use of vitamin E supplementation without the concurrent use of vitamin C 
(Johansen et al., 2005, Penckofer et al., 2002, Wierzba, 2005, Robinson et al., 2006, Willcox et 
al., 2008). Other limitations include: some trials are gender-specific (comprising either men 
or women); lack of pharmacokinetic data of these antioxidants, before and after treatment, 
so as to ascertain if these antioxidants reached the target cells/tissues in adequate 
concentrations; no data to show that effects of different doses of each antioxidant were 
investigated so as to obtain and select optimal dose; the suppression of gamma-tocopherol 
by alpha-tocopherol; vitamins inappropriately administered relative to meal ingestion; and 
poor patient compliance are some of the issues that may contribute to the failure of 
antioxidants in clinical studies (Johansen et al., 2005, Penckofer et al., 2002, Wierzba, 2005, 
Robinson et al., 2006, Willcox et al., 2008). Some endpoints that were not directly related to 
oxidative stress such as mortality were used in some trials (Johansen et al., 2005). Hence, 
limited research and findings are available on the effects of antioxidants in diabetic patients. 
However, available evidences in small or medium sample-sized diabetic studies, both 
experimental and clinical, suggest antioxidants might play a role in the management of 
diabetes mellitus.  
In diabetic rats with neuropathy, ǂ-lipoic acid supplementation ameliorated oxidative stress 
parameters and improved lesions of diabetic neuropathy such as conduction velocity of the 
digital nerve, deficits in nerve conduction and nerve blood flow (Coppey et al., 2001). 
Evidence suggests that antioxidants can inhibit some of the pathways of diabetic 
complications such as protein kinase C-signaled increases in TGF- in mesangial cells (Scott 
and King, 2004). Similarly, antioxidant treatment prevented the elevation in the levels of 
protein kinase C-beta, NAD(P)H oxidase subunit p47phox, BCL-2-associated X protein, 3-
nitrotyrosine, fibronectin and poly (ADP) ribose in the retina of diabetic rats (Ihnat et al., 
2007). In the kidney of diabetic rats, honey supplementation considerably reduced 
hyperglycemia, attenuated antioxidant enzymes, ameliorated oxidative stress markers and 
reduced mesangial matrix expansion and glomerular basement membrane thickness 
(Erejuwa et al., 2010a, Erejuwa et al., 2010c).  
In patients with type 1 diabetes, supplementation with vitamins E and/or C combination 
ameliorated oxidative stress and improved endothelium-dependent vasorelaxation 
(Johansen et al., 2005, Rahimi et al., 2005). A study found that supplementation with 
combined chromium (Cr) and vitamins C and E ameliorated oxidative stress, reduced 
fasting blood glucose, HbA1c and insulin resistance in type 2 diabetes (Lai, 2008). Similarly, 
a recent study reported that vitamin E supplementation significantly reduced 
malondialdehyde (MDA) levels and increased the concentrations of GSH and vitamin E in 
type 1 diabetic patients (Gupta et al., 2011). The study also found a negative correlation 
between oxidative stress marker (MDA) and antioxidants (vitamin E and GSH) and a 
positive correlation between exogenously administered antioxidant (vitamin E) and 
endogenous antioxidant (GSH) (Gupta et al., 2011). However, the study showed that 
vitamin E supplementation in type 1 diabetic patients did not produce significant effects in 
metabolic parameters (Gupta et al., 2011). In patients with type 1 diabetes mellitus, vitamins 
C and E supplementation ameliorated oxidative stress markers, improved vascular 
dysfunction, retinal blood flow and creatinine clearance (Scott and King, 2004). These 
studies indicate that antioxidants could play a role in the management of  diabetes mellitus. 
However, considering that diabetes mellitus is a disorder with multiple etiology and 
metabolic derangements, antioxidant supplementation alone is likely to be less effective. 
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This is corroborated by findings of Gupta and co-workers (2011). That could also explain the 
failure of antioxidants in clinical trials.  
6.5 Could there be a role of hypoglycemic drugs (and/or insulin) and antioxidants in 
the management of diabetic complications? 
A closer look at the various mechanistic pathways implicated in the pathogenesis of diabetic 
complications indicates that hyperglycemia-enhanced polyol pathway (via depletion of 
intracellular NADPH) and O2− inhibition of G6PDH (via hyperglycemia-enhanced O2− 
overproduction) would play a major role in impairing antioxidant defenses. This will 
increase intracellular susceptibility to oxidative stress during diabetes. As regards evidence, 
very few studies have investigated the effects of combined hypoglycemic agents and 
antioxidants in diabetic rodents or patients. Interestingly, all these studies found beneficial 
effects of combination of these two agents in both animals and human with diabetes 
mellitus. A study that investigated the effects of 4-week insulin and/or antioxidant (vitamin 
E and C) supplementation in diabetic rats found that the antioxidant treatment improved 
some of the oxidative stress parameters whereas insulin treatment prevented weight loss 
and ameliorated the activities and expression of antioxidant enzymes. In contrast, the 
combination of insulin and antioxidants resulted in normalization of all measurements 
including oxidative stress parameters (Sindhu et al., 2004).  
Similarly, comparison of the effects of glibenclamide alone or combined with honey in 
pancreas of diabetic rats indicated that, even though glibenclamide reduced hyperglycemia, 
it only partially ameliorated oxidative stress parameters (most of the data were 
insignificant) (Erejuwa et al., 2011b). However, the combination of glibenclamide and honey 
significantly reduced hyperglycemia and ameliorated oxidative stress parameters in 
pancreas of diabetic rats (Erejuwa et al., 2011b). A similar study also showed that a 
combination of glibenclamide and metformin produced a limited antioxidant effect 
compared to when they were combined with honey in pancreas of diabetic rats (Erejuwa et 
al., 2010b). In the kidney of diabetic rats treated with metformin and/or glibenclamide, 
impaired antioxidant defenses were reported. In contrast, metformin and/or glibenclamide 
combined with honey significantly ameliorated oxidative stress parameters and restored the 
activities of  antioxidant enzymes in the kidney of diabetic rats (Erejuwa et al., 2011a).  
In type 1 and type 2 diabetic patients, a study found that while optimal glycemic control 
reduced the levels of MDA and increased the levels of GSH and vitamin E, it did not 
normalize the oxidative stress parameters (Chugh et al., 1999). However, after 4 weeks of 
vitamin E supplementation, the levels of oxidative stress markers were further reduced 
while those of endogenous antioxidants were increased compared to the optimal control 
values (without antioxidant treatment) (Chugh et al., 1999). A similar beneficial effect of 
vitamin E supplementation and optimal glycemic control was also reported in type 2 
diabetic patients (Sharma et al., 2000). A number of other studies have also shown that 
antioxidants reduce glucose levels, improve insulin secretion and insulin resistance during 
diabetes (Penckofer et al., 2002). Moreover, a study found that in type 1 diabetic patients, 
normalization of glucose levels did not ameliorate hyperglycemia-induced endothelial 
dysfunction (Ceriello et al., 2007). The authors reported that, neither insulin nor vitamin C 
was able to ameliorate oxidative stress or normalize endothelial dysfunction (Ceriello et al., 
2007). On the contrary, combination of insulin and vitamin C significantly decrease the 
www.intechopen.com
 
Oxidative Stress and Diseases 
 
236 
intensity of oxidative stress and normalized endothelial dysfunction in type 1 diabetic 
patients (Ceriello et al., 2007).  
A critical analysis of the mechanistic pathways of hyperglycemia-induced diabetic 
complications indicates that they are all characterized by increased formation of ROS and 
impaired antioxidant defense network, which would further exacerbate oxidative stress and 
damage. In other words, these pathways begin and end with oxidative stress. Besides, 
evidence indicates that postprandial hyperglycemic fluctuations can cause endothelial 
dysfunction and induce oxidative stress in diabetic subjects and even in euglycemic subjects. 
Hence, findings from these studies clearly indicate that it is oxidative stress all over in 
diabetes mellitus and its complications. Moreover, the data from experimental and clinical 
studies indicate that there is a role for co-administration of hypoglycemic drugs or insulin 
and antioxidants in diabetes mellitus. It is possible that normalization of hyperglycemia may 
be achieved with hypoglycemic drugs, insulin, their combinations or even via pancreatic 
transplant. However, in patients with diabetic complications, whether euglycemia is 
achieved and/or maintained, oxidative stress (and oxidative stress-induced sequelae) 
becomes an independent entity. Thus, oxidative stress, as a possible independent entity, in 
diabetes mellitus necessitates antioxidant therapy. On account of these observations, 
findings and data, there seems little doubt that antioxidant therapy or other therapeutic 
intervention of oxidative stress in combination with hypoglycemic drugs or insulin should 
result in better management of diabetes mellitus. This should also prevent or reduce ROS-
linked diabetic complications.  
6.6 Other potential beneficial effects of hypoglycemic drugs (and/or insulin) and 
antioxidants in diabetes mellitus 
Diabetes mellitus is characterized by impairments in renal and hepatic function as well as 
impaired metabolism of glucose, lipid and protein. Lipid abnormalities and induction of 
oxidative stress enhance the oxidation and glycation of low-density lipoproteins (LDLs), 
thereby exacerbate endothelial dysfunction (Penckofer et al., 2002). Studies have shown that 
antioxidants and some hypoglycemic drugs can prevent oxidation of LDL (Fava et al., 2002, 
Maritim et al., 2003, Rahimi et al., 2005). Besides, evidence indicates that antioxidants can 
ameliorate lipid abnormalities (Rahimi et al., 2005, Erejuwa et al., 2011d). The beneficial 
effects of antioxidants on glycemic control (blood glucose, fructosamine and glycosylated 
hemoglobin) in diabetes have also been documented (Rahimi et al., 2005, Lai, 2008, Erejuwa 
et al., 2010a;  2011d). Furthermore, antioxidants improve C-peptide and insulin levels as 
well as insulin resistance in diabetes mellitus (Rahimi et al., 2005, Lai, 2008, Erejuwa et al., 
2011d). Co-administration of hypoglycemic drugs (glibenclamide or metformin) and 
antioxidant (honey) considerably improved glycemic control and lipid parameters in 
diabetic rats more than the effects produced by individual hypoglycemic drug (Erejuwa et 
al., 2011d). It is worth mentioning that other non-antioxidant constituents of honey, such as 
fructose and oligosaccharides, might contribute to this improved glycemic control and lipid 
parameters. In addition, antioxidants ameliorated and improved impaired renal function 
which has been documented in diabetes mellitus (Slyvka et al., 2009, Erejuwa et al., 2011d) 
or in combination with hypoglycemic drugs may produce synergism (Erejuwa et al., 2011d). 
In the duodenum and jejunum of diabetic rats, a number of alterations in the brush border 
membrane (BBM) fluidity, non-enzymatic glycation, oxidative stress and damage have been 
www.intechopen.com
Oxidative Stress in Diabetes Mellitus: 
Is There a Role for Hypoglycemic Drugs and/or Antioxidants? 
 
237 
reported (Bhor and Sivakami, 2003). Similarly, increased protein glycation and lipid 
peroxidation might exacerbate diabetes-related alterations in BBM fluidity (Watala and 
Winocour, 1992). Therefore, antioxidants may ameliorate intestinal oxidative stress and 
improve BBM fluidity, thereby promote healing and enhance gastrointestinal tract health in 
diabetes mellitus. This might impact positively on glycemic control. Antioxidants may also 
augment bioavailability of essential macronutrients or co-administered hypoglycemic drugs 
(Faria et al., 2009). Furthermore, antioxidants may help to ameliorate liver damage and 
hepatic oxidative stress which are common in diabetes mellitus (Dias et al., 2005, Erejuwa et 
al., 2012b). Considering the role of liver in glucose homeostasis and the fact that some 
hypoglycemic agents (e.g. glibenclamide) mediate their effects via liver, these hepatic effects 
of antioxidants combined with those of hypoglycemic drugs may enhance liver functions 
and contribute to improved glycemic control. Moreover, evidence suggests that the use of 
antioxidants is associated with reduced weight gain (Razquin et al., 2009, Erejuwa et al., 
2012a), therefore, co-administration of antioxidants and hypoglycemic agents, especially 
glibenclamide, may be beneficial in type 2 diabetic patients, majority of whom are obese. 
Majority of diabetic patients end up developing hypertension which further increases the 
risk of developing diabetic complications including cardiovascular events. Interestingly, 
oxidative stress is also implicated in the pathogenesis and/or complications of 
hypertension. Therefore, a combination of hypoglycemic drugs and antioxidants, via 
improved glycemic control and amelioration of oxidative stress, may help to prevent or 
delay the development of hypertension and diabetic complications (Erejuwa et al., 2011c, 
2012a). Besides, the combination of both agents may help to minimize the adverse effects or 
toxicities of hypoglycemic agents. The use of antioxidants may necessitate lower doses of 
hypoglycemic agents to achieve the same therapeutic effect, thereby limiting the side or 
adverse effects of these drugs. 
7. Conclusions 
These studies indicate that hyperglycemia exerts long-term injurious effects in patients with 
type 1 and type 2 diabetes mellitus. Similar long-lasting detrimental effects of 
hyperglycemia also occur in diabetic animals. In both animals and humans with diabetes, 
glycemic control only delays the development or progression of diabetic complications. It 
does not prevent or completely restore diabetic complications. In few cases in which good 
glycemic control or cure of diabetes does prevent diabetic complications, it has to be 
initiated at a very early stage of the disease and maintained for several years. This is 
probably impracticable in the larger diabetic population. Evidence indicates it is not easy to 
achieve and/or maintain glycemic control in many diabetic patients close to the 
physiological range commonly observed in their healthy counterparts. Together with recent 
findings which demonstrate the deleterious effect of intensive therapy of hyperglycemia, it 
can be inferred that any therapeutic option that target hyperglycemia alone is not only 
limited and ineffective but may also be detrimental in diabetic patients. In view of the 
alarming rate of global prevalence of diabetes mellitus and the associated complications, 
morbidity and mortality, there is an urgent need for a better or new therapeutic 
management. While efforts are being made by researchers and scientists to unravel the main 
cause(s) of diabetes mellitus, it is high time clinicians, physicians and diabetologists began 
to look for an alternative and/or a complementary therapy to the current management of 
diabetes mellitus.  
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At the moment, one of such options or alternatives is the prospective of managing diabetes 
mellitus by targeting both hyperglycemia and oxidative stress simultaneously. As the data 
presented in this chapter have revealed, co-administration of oral hypoglycemic drugs 
(and/or insulin) and antioxidants might prove to be a better therapy in the management of 
diabetes mellitus. This is because, with the combination, hypoglycemic drugs (and/or 
insulin) will target hyperglycemia to improve glycemic control and reduce hyperglycemia-
enhanced ROS production. In addition, administration of antioxidants will help to scavenge 
or eliminate RS including those generated in the various pathways highlighted in this 
chapter. Besides, many antioxidants have hypoglycemic effect which may also contribute to 
improved glycemic control. The co-administration of these two agents will help to minimize 
the level of oxidative stress in the vasculature and other targets of diabetic complications 
such as kidney (reducing diabetic nephropathy), retina (reducing diabetic retinopathy), 
nerves (reducing diabetic neuropathy) and heart (reducing diabetic cardiomyopathy). 
Moreover, evidence has shown that the pancreas and the liver are also target of oxidative 
stress in diabetes mellitus. Hence, co-administration of antioxidants will help to ameliorate 
oxidative stress in these tissues and organs (pancreas and liver) which play key roles in 
glucose homeostasis in diabetes mellitus.  
In addition to improved glycemic control and amelioration of oxidative stress, evidence 
suggests that co-administration of hypoglycemic drugs and antioxidants may exert other 
beneficial effects on gastrointestinal tract, lipid profile, renal function and others which will 
contribute to better management of diabetic patients. Considering the limitations with 
antioxidants, coupled with the latest advances in our understanding of the various 
mechanisms involved in ROS formation, other interventions such as inhibition of the 
mitochondrial ROS overproduction, developing mitochondria-targeted antioxidants, 
blockage of hyperglycemia-induced mechanistic pathways are viable therapeutic options. 
This chapter has shown that the prospective of managing diabetes mellitus more effectively 
by targeting both hyperglycemia and oxidative stress simultaneously holds much promise. 
This new therapeutic option is worth investigating in patients with diabetes mellitus. Hence, 
both small and large, well designed, randomized clinical trials that examine the effect of 
combination of hypoglycemic drugs (and/or insulin) and specific antioxidants in patients 
with type 1 or type 2 diabetes mellitus are recommended. This may revolutionize the 
management of diabetes mellitus, at least in the interim, while attempts are being made to 
discover its main cause(s) and develop more potent and effective antidiabetic drugs.  
8. Dedication 
This chapter is dedicated to the memory of my dad, Educator Sephaniah Adeyemi Erejuwa, 
who battled diabetes mellitus and later succumbed to its complications. It is also dedicated 
to millions of people globally who are suffering from this disorder and its complications 
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